Bayer (BAYN.DE XETRA) up 6.50% to €45.58: watch €42 support and analyst targets

BAYN.DE stock led XETRA volume on 24 Feb 2026 after a 6.50% intraday gain to €45.58 on 3,963,565.00 shares traded. The move closed the market session in Germany and placed Bayer AG (BAYN.DE) among the most active names on the day. Investors cited improving cash flow metrics and imminent earnings on 04 Mar 2026 as drivers. We track volume, valuation and technicals to explain why BAYN.DE stock drew active trading and what to watch next.

BAYN.DE stock intraday movers and liquidity

Bayer AG (BAYN.DE) closed XETRA trading at €45.58, up 6.50% from the previous close of €42.80. Volume hit 3,963,565.00 versus an average of 3,887,175.00, marking it a most-active stock on 24 Feb 2026. The session high was €46.33 and the low was €45.11. One claim per fact: higher-than-average volume confirms real buying interest rather than isolated prints. For live gauges and order flow checks see our BAYN.DE page on Meyka AI for real-time updates.

BAYN.DE stock fundamentals and valuation

Bayer’s trailing EPS is -0.20 and reported PE is -211.70, reflecting recent negative earnings. Market capitalization stands at €41,595,835,632.00. Key valuation metrics show price-to-sales 0.92, price-to-book 1.42, and free cash flow yield around 9.36%. One claim per line: the company generates strong operating cash flow per share (6.85) despite net income volatility. Balance-sheet signals include debt-to-equity 1.34 and netDebt/EBITDA 5.53, which raise leverage risk for conservative investors.

BAYN.DE stock technicals: trend, support and resistance

Technical indicators show RSI 42.75 and ADX 38.12, suggesting a strong directional trend with room to move. Bollinger middle band sits at €45.28 and lower band at €42.44, which lines up with short-term support near €42.00. One claim per metric: MACD histogram is negative (MACD 0.58, signal 1.30) indicating short-term momentum cooling. Watch the year high €49.78 as immediate resistance and the 50-day average €41.42 as a dynamic support zone.

Meyka AI rates BAYN.DE with a score out of 100 and forecast

Meyka AI rates BAYN.DE with a score out of 100: 68.10, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. One claim per sentence: the grade balances solid cash flow and valuation against elevated leverage and negative EPS. Meyka AI’s forecast model projects a monthly price of €49.38 and a quarterly price of €59.96. Compared with the current price €45.58, the monthly forecast implies an upside of 8.34% and the quarterly forecast implies 31.65% upside. Forecasts are model-based projections and not guarantees.

Catalysts, risks and BAYN.DE stock outlook

Catalysts include the upcoming earnings release on 04 Mar 2026 and continued strength in Crop Science sales. One claim per sentence: positive free cash flow growth and research partnerships support upside. Primary risks include high netDebt/EBITDA 5.53, negative EPS, and sector margin pressure. Keep an eye on regulatory or litigation headlines and sector rotations in Healthcare that can amplify volatility for BAYN.DE stock.

Trading strategy for most-active BAYN.DE stock

For active traders the structure is clear: intraday support around €42.00 and resistance near €49.78. One claim per sentence: use tighter stops if exposure is sizeable given leverage metrics. Longer-term investors should weigh free cash flow yield 9.36% against debt-to-equity 1.34 and consider a staged entry if price retests the 50-day average €41.42. For real-time signals and ranked alerts visit our BAYN.DE stock page on Meyka AI.

Final Thoughts

BAYN.DE stock closed the XETRA session on 24 Feb 2026 at €45.58 with above-average volume, signalling renewed investor attention ahead of Bayer’s earnings on 04 Mar 2026. The company shows robust cash flow per share (€6.85) and attractive price-to-book (1.42), but carries elevated leverage (netDebt/EBITDA 5.53) and a negative EPS (-0.20). Meyka AI’s forecast model projects a near-term monthly target of €49.38 (+8.34% vs €45.58) and a quarterly target of €59.96 (+31.65%). Use those model targets as scenario anchors, not guarantees. Active traders should watch €42.00 support and €49.78 resistance; long-term investors should measure earnings outcomes and leverage reduction progress before adding exposure. Meyka AI provides this as AI-powered market analysis and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.